Charles Schwab Investment Management Inc. Grows Position in Twist Bioscience Co. (NASDAQ:TWST)

Charles Schwab Investment Management Inc. grew its stake in Twist Bioscience Co. (NASDAQ:TWST - Free Report) by 4.9% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 524,942 shares of the company's stock after buying an additional 24,582 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.90% of Twist Bioscience worth $23,717,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in TWST. Caprock Group LLC boosted its stake in shares of Twist Bioscience by 2.9% in the second quarter. Caprock Group LLC now owns 7,851 shares of the company's stock worth $387,000 after acquiring an additional 220 shares during the last quarter. Signaturefd LLC lifted its stake in Twist Bioscience by 63.0% during the third quarter. Signaturefd LLC now owns 792 shares of the company's stock worth $36,000 after purchasing an additional 306 shares in the last quarter. Arizona State Retirement System lifted its position in shares of Twist Bioscience by 1.9% during the second quarter. Arizona State Retirement System now owns 16,187 shares of the company's stock worth $798,000 after purchasing an additional 308 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of Twist Bioscience by 3.5% in the second quarter. Massachusetts Financial Services Co. MA now owns 9,279 shares of the company's stock worth $457,000 after acquiring an additional 312 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Twist Bioscience by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,119 shares of the company's stock worth $98,000 after purchasing an additional 381 shares during the period.

Insider Transactions at Twist Bioscience

In other news, insider Dennis Cho sold 1,507 shares of Twist Bioscience stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $48.00, for a total transaction of $72,336.00. Following the completion of the sale, the insider now directly owns 91,163 shares in the company, valued at $4,375,824. The trade was a 1.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Emily M. Leproust sold 14,334 shares of the company's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $44.60, for a total transaction of $639,296.40. Following the transaction, the chief executive officer now directly owns 589,552 shares in the company, valued at $26,294,019.20. The trade was a 2.37 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 98,118 shares of company stock valued at $4,391,151 over the last three months. 3.92% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

TWST has been the topic of a number of recent analyst reports. Leerink Partners increased their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a "market perform" rating in a research report on Thursday, October 17th. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an "overweight" rating on the stock in a research note on Tuesday, November 19th. Evercore ISI upped their price objective on Twist Bioscience from $52.00 to $56.00 and gave the stock an "outperform" rating in a research report on Tuesday, October 1st. Robert W. Baird raised their target price on Twist Bioscience from $46.00 to $48.00 and gave the stock an "outperform" rating in a research report on Tuesday, November 19th. Finally, Scotiabank upped their price target on Twist Bioscience from $50.00 to $54.00 and gave the company a "sector outperform" rating in a report on Tuesday, November 19th. One analyst has rated the stock with a sell rating, one has given a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $51.00.

Twist Bioscience Stock Performance

TWST stock traded up $1.96 on Friday, reaching $52.70. The company had a trading volume of 511,452 shares, compared to its average volume of 943,543. The company's fifty day moving average is $44.23 and its 200 day moving average is $46.34. The company has a market cap of $3.13 billion, a P/E ratio of -14.09 and a beta of 1.82. Twist Bioscience Co. has a 1 year low of $24.81 and a 1 year high of $60.90.

Twist Bioscience Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.